Paraoxonase and arylesterase activity with oxidative status in children with thalassemia major

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 8, 2009, Pages 583-587

  Cakmak, Alpay ^a   Soker, Murat ^a   Koc, Ahmet ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

thalassemia major; Arylesterase; Oxidative status; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; FERRITIN; IRON; PEROXIDE; CARBOXYLESTERASE;

ARTICLE; ATHEROGENESIS; BETA THALASSEMIA; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR; ATHEROSCLEROSIS; BLOOD; ENZYMOLOGY; OXIDATION REDUCTION REACTION; PRESCHOOL CHILD;

ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BETA-THALASSEMIA; CARBOXYLIC ESTER HYDROLASES; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IRON; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDES;

EID: 68849089272     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181acd93d     Document Type: Article

References (31)

1. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassaemias. In: Weatherall DJ, Clegg B, eds. The Thalassaemia Syndromes. 4th ed. Oxford: Blackwell Science; 2001:133-191.
2. Livrea MA, Tesoriere L, Maggio A, et al. Oxidative modification of low density lipoprotein and atherogenetic risk in beta-thalassemia. Blood. 1998;92:3936-3942. (Pubitemid 28525220)
3. Brizzi P, Isaja T, D'Agata A, et al. Oxidized LDL antibodies (OLAB) in patients with b-thalassemia major. J Atheroscl Thromb. 2002;9:139-144.
4. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
5. Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin. 2003;121:537-548.
6. Chakraborty D, Bhattacharyya M. Antioxidant defense status of red blood cells of patients with b-thalassemia and Ebeta-thalassemia. Clin Chim Acta. 2001;305:123-129. (Pubitemid 32201969)
7. Kassab-Chekir A, Laradi S, Ferchichi S, et al. Oxidant, antioxidant status and metabolic data in patients with betathalassemia. Clin Chim Acta. 2003;338:79-86. (Pubitemid 37456693)
8. Dhawan V, Kumar KHR, Marwaha RK, et al. Antioxidant status in children with homozygous beta thalassemia. Indian Pediatr. 2005;42:1141-1145. (Pubitemid 43373140)
9. Calandra S, Bertolini S, Pes GM, et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Semin Vasc Med. 2004;4:271-278. (Pubitemid 40094492)
10. Morales NP, Charlermchoung C, Luechapudiporn R, et al. Lipid fluidity at different regions in LDL and HDL of beta-thalassemia/Hb E patients. Biochem Biophys Res Commun. 2006;350:698-703. (Pubitemid 44547903)
11. Tesoriere L, Arpa D, Moggio A, et al. Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia. Atheroseclerosis. 1998;137:429-435. (Pubitemid 28215889)
12. Vives Corrons JL, Miguel-Garcia A, Pujades MA, et al. Increased susceptibility of microcytic red blood cells to in vitro oxidative stress. Eur J Haematol. 1995;55:327-331.
13. Tassiopoulos S, Deftereos S, Konstantopoulos K, et al. Does heterozygous beta-thalassemia confer a protection against coronary artery disease? Ann N Y Acad Sci. 2005;1054:467-470.
14. Sodergren E, Nourooz ZJ, Berglund L, et al. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. J Biochem Biophys Methods. 1998;37:137-146. (Pubitemid 28517930)
15. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126-1138.
16. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem. 1992;30:391-395.
17. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112-119. (Pubitemid 38077161)
18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103-1111. (Pubitemid 41797751)
19. Kosecik M, Erel O, Sevinc E, et al. Increased oxidative stress in children exposed to passive smoking. Intern J Cardiol. 2005;100:61-64. (Pubitemid 40487937)
20. Nourooz ZJ. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999;300:58-62.
21. Barrano B, Bertrand G, Isaja T, et al. Plasma homocysteine is not involved in the thrombotic risk of b-thalassemia major patients. Acta Haematologica. 2000;104:148-150. (Pubitemid 32045985)
22. Knutson MD, Walter PB, Ames BN, et al. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J Nutr. 2000;130:621-628.
23. Walter PB, Knutson MD, Paler-Martinez A, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA. 2002;99:2264-2269. (Pubitemid 34169049)
24. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in bthalassaemia patients. Eur J Clin Invest. 2002;32:55-60. (Pubitemid 41704989)
25. Walter PB, Fung E, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded Patients with bthalassemia or sickle cell disease. Br J Haematol. 2006;135:254-263. (Pubitemid 44401624)
26. Laksmitawati DR, Handayani S, Udyaningsih-Freisleben SK, et al. Iron status and oxidative stress in b-thalassemia patients in Jakarta. Biofactors. 2003;19:53-62. (Pubitemid 38073144)
27. Tesoriere L, D'Arpa D, Butera D, et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic Res. 2001;34:529-540. (Pubitemid 32492691)
28. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37:77-83. (Pubitemid 36124333)
29. Luechapudiporn R, Morales NP, Fucharoen S, et al. The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in b-thalassemia/Hb E. Clin Chem Lab Med. 2006;44:574-581. (Pubitemid 43735629)
30. Maioli M, Vigna GB, Tonolo G. Plasma lipoprotein composition, apolipoprotein (a) concentration and isoforms in beta thalassemia. Atherosclerosis. 1997;131:127-133. (Pubitemid 27240105)
31. Goldfarb AW, Rachmilewitz EA, Eisenberg S. Abnormal low and high density lipoproteins in homozygous beta thalassemia. Br J Haematol. 1991;79:481-486.